CD8A and neoplasm: Collectively, these studies propose that early dysfunctional tumor-specific PD-1+ CD8+ T cells in sites of micrometastases, lymph nodes and blood may be the actual target cells of therapeutic anti-PD-1 antibodies, as they expand, infiltrate the tumor and most likely also engage in the anti-tumor immune defense [46,62].